How Metformin Slows Cancer Growth Through AMPK Activation

16 Oct 2025 · 1 min

Watch on YouTube

0:38

In this segment, the speaker explains that mTOR is a cellular growth regulator that must remain balanced; excessive mTOR activity leads to aggressive cell proliferation, so mTOR inhibition is a strategy to curb such growth. The speaker notes that metformin, a common diabetes drug, functions as an mTOR‑inhibiting agent by activating the enzyme AMPK. AMPK activation is a target of many contemporary cancer therapies because it suppresses tumor growth and progression. Thus, metformin’s ability to trigger AMPK links it to potential anti‑cancer effects.

Chapters

mTOR is one of those things your body naturally does and you want to have it in balance. mTOR inhibition is used if you have too aggressive growth of cells and you want to cut them off. You can use an mTOR inhibiting substance to help do that. So it turns out that metformin does that. It helps with activating an enzyme that's targeted by lots of cancer drugs nowadays called AMPK. And the reason that in cancer therapies they're always trying to get AMPK to activate is that AMPK helps to inhibit cancer growth and progression. So that's obviously very important there as well.